Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Lymphoma

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 308 articles:
HTML format
Text format



Single Articles


    October 2019
  1. HERBER M, Mertz P, Dieudonne Y, Guffroy B, et al
    Primary immunodeficiencies and lymphoma: a systematic review of literature.
    Leuk Lymphoma. 2019 Oct 3:1-11. doi: 10.1080/10428194.2019.1672056.
    PubMed     Text format     Abstract available


    September 2019
  2. MYLES N, Giri P, Chim I, Kodituwakku A, et al
    The utility of CD200 expression and modified Matutes score in the diagnostic differentiation of mantle cell lymphoma and chronic lymphocytic leukemia using flow cytometry.
    Leuk Lymphoma. 2019 Sep 27:1-3. doi: 10.1080/10428194.2019.1663420.
    PubMed     Text format    


  3. NOVO M, Nowakowski GS, Habermann TM, Witzig TE, et al
    Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?
    Leuk Lymphoma. 2019 Sep 26:1-10. doi: 10.1080/10428194.2019.1663422.
    PubMed     Text format     Abstract available


  4. PORRATA LF
    Beware of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Sep 26:1-2. doi: 10.1080/10428194.2019.1668940.
    PubMed     Text format    


  5. GHAFOOR T
    Prognostic factors in pediatric Hodgkin lymphoma: experience from a developing country.
    Leuk Lymphoma. 2019 Sep 19:1-7. doi: 10.1080/10428194.2019.1665666.
    PubMed     Text format     Abstract available


  6. HU B, Nastoupil LJ, Loghavi S, Westin JR, et al
    De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.
    Leuk Lymphoma. 2019 Sep 18:1-9. doi: 10.1080/10428194.2019.1663418.
    PubMed     Text format     Abstract available


  7. NAKAYAMA S, Morita Y, Espinoza JL, Rai S, et al
    Multiple cytokine-producing B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma with autoimmune hemolytic anemia.
    Leuk Lymphoma. 2019 Sep 18:1-3. doi: 10.1080/10428194.2019.1665665.
    PubMed     Text format    


  8. TAPARRA K, Liu H, Polley MY, Ristow K, et al
    Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.
    Leuk Lymphoma. 2019 Sep 13:1-11. doi: 10.1080/10428194.2019.1663419.
    PubMed     Text format     Abstract available


  9. WEI L, Wang J, Ye J, Yang L, et al
    Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study.
    Leuk Lymphoma. 2019 Sep 13:1-7. doi: 10.1080/10428194.2019.1663421.
    PubMed     Text format     Abstract available


  10. JOSHI M, Taper J, Forsyth C, Rowlings P, et al
    Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation.
    Leuk Lymphoma. 2019 Sep 12:1-7. doi: 10.1080/10428194.2019.1660968.
    PubMed     Text format     Abstract available


  11. THUMMALAPALLI R, Sena LA, Probasco JC, Gladstone DE, et al
    Checkpoint inhibitor-induced autoimmune encephalitis reversed by rituximab after allogeneic bone marrow transplant in a patient with Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Sep 10:1-3. doi: 10.1080/10428194.2019.1658104.
    PubMed     Text format    


    August 2019
  12. MOREIRA J, Platanias LC, Adekola KUA
    It's all about the CD3+ T-cells: how circulating immune cell subset analyses can predict early relapse in Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Aug 27:1-3. doi: 10.1080/10428194.2019.1646909.
    PubMed     Text format    


  13. GO H, Jang JY, Kim CW, Huh J, et al
    Identification of microRNAs modulated by DNA hypomethylating drugs in extranodal NK/T-cell lymphoma.
    Leuk Lymphoma. 2019 Aug 23:1-9. doi: 10.1080/10428194.2019.1654096.
    PubMed     Text format     Abstract available


  14. FUKUHARA N, Yamamoto G, Tsujimura H, Chou T, et al
    Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.
    Leuk Lymphoma. 2019 Aug 22:1-5. doi: 10.1080/10428194.2019.1654100.
    PubMed     Text format    


  15. DECKER DP, Egan PC, Zayac AS, Treaba DO, et al
    Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma.
    Leuk Lymphoma. 2019 Aug 21:1-4. doi: 10.1080/10428194.2019.1654097.
    PubMed     Text format    


  16. ZEREMSKI V, Fischer T, Schalk E
    Dose reduction and high-risk disease as risk factors for early death in primary CNS lymphoma.
    Leuk Lymphoma. 2019 Aug 8:1-3. doi: 10.1080/10428194.2019.1650176.
    PubMed     Text format    


  17. ALBARMAWI H, Nagarajan M, Sun K, Gandhi AB, et al
    Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data.
    Leuk Lymphoma. 2019 Aug 7:1-9. doi: 10.1080/10428194.2019.1648804.
    PubMed     Text format     Abstract available


  18. ONG SY, Phipps C, Nagarajan C, Tang T, et al
    Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia.
    Leuk Lymphoma. 2019 Aug 5:1-3. doi: 10.1080/10428194.2019.1648805.
    PubMed     Text format    


  19. GUNTHER JR, Park C, Dabaja BS, Milgrom SA, et al
    Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function().
    Leuk Lymphoma. 2019 Aug 2:1-5. doi: 10.1080/10428194.2019.1644333.
    PubMed     Text format    


    July 2019
  20. TRACHTENBERG E, Gurion R, Mashiach T, Tadmor T, et al
    Recognizing severe fatigue and decline in quality of life in Hodgkin lymphoma survivors.
    Leuk Lymphoma. 2019 Jul 22:1-6. doi: 10.1080/10428194.2019.1641803.
    PubMed     Text format     Abstract available


  21. LOW SK, Zayan AH, Istanbuly O, Minh Duc NT, et al
    Prognostic factors and nomogram for survival prediction in patients with primary pulmonary lymphoma: a SEER population-based study.
    Leuk Lymphoma. 2019 Jul 19:1-11. doi: 10.1080/10428194.2019.1633636.
    PubMed     Text format     Abstract available


  22. YAMAGUCHI J, Chinen Y, Takimoto-Shimomura T, Nagata H, et al
    Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Jul 18:1-8. doi: 10.1080/10428194.2019.1636982.
    PubMed     Text format     Abstract available


  23. WATANABE J, Natsumeda M, Kanemaru Y, Okada M, et al
    Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma.
    Leuk Lymphoma. 2019 Jul 15:1-3. doi: 10.1080/10428194.2019.1639169.
    PubMed     Text format    


  24. KUZICH JA, Hutchison AP, Lim KJC, Smallbone P, et al
    Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia.
    Leuk Lymphoma. 2019 Jul 15:1-9. doi: 10.1080/10428194.2019.1637865.
    PubMed     Text format     Abstract available


  25. FERRARINI I, Rigo A, Zamo A, Vinante F, et al
    Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment.
    Leuk Lymphoma. 2019 Jul 14:1-11. doi: 10.1080/10428194.2019.1636983.
    PubMed     Text format     Abstract available


  26. QI F, Chen B, Wang J, Lin X, et al
    Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era.
    Leuk Lymphoma. 2019 Jul 12:1-10. doi: 10.1080/10428194.2019.1599111.
    PubMed     Text format     Abstract available


  27. HUETTL KS, Staiger AM, Stehle A, Bonzheim I, et al
    Peripheral T-cell lymphoma NOS arising in patients with classical Hodgkin lymphoma of cytotoxic phenotype.
    Leuk Lymphoma. 2019 Jul 10:1-4. doi: 10.1080/10428194.2019.1636987.
    PubMed     Text format    


  28. OLLILA TA, Reagan JL, Olszewski AJ
    Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base.
    Leuk Lymphoma. 2019 Jul 9:1-8. doi: 10.1080/10428194.2019.1639166.
    PubMed     Text format     Abstract available


  29. SALVI F, Luminari S, Tucci A, Massidda S, et al
    Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (>/=70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL).
    Leuk Lymphoma. 2019 Jul 8:1-9. doi: 10.1080/10428194.2019.1608529.
    PubMed     Text format     Abstract available


  30. DELAMAIN MT, Gomez GVB, Lourenco GJ, de Souza CA, et al
    Increased risk of Hodgkin lymphoma in males with inherited T lymphocyte receptor programed death-1 deficiency.
    Leuk Lymphoma. 2019 Jul 8:1-5. doi: 10.1080/10428194.2019.1636988.
    PubMed     Text format    


  31. LOH KP, Baran A, Lee CY, Alshaibani A, et al
    Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation.
    Leuk Lymphoma. 2019 Jul 8:1-4. doi: 10.1080/10428194.2019.1639172.
    PubMed     Text format    


  32. GOLDSTEIN JS, Switchenko JM, Behera M, Flowers CR, et al
    Insurance status impacts overall survival in Burkitt lymphoma.
    Leuk Lymphoma. 2019 Jul 5:1-10. doi: 10.1080/10428194.2019.1623884.
    PubMed     Text format     Abstract available


  33. CANDELARIA M, Gonzalez DE, Delamain MT, Bar DO, et al
    Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.
    Leuk Lymphoma. 2019 Jul 4:1-11. doi: 10.1080/10428194.2019.1633632.
    PubMed     Text format     Abstract available


  34. OON ML, Hoppe MM, Fan S, Phyu T, et al
    The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Jul 1:1-11. doi: 10.1080/10428194.2019.1633629.
    PubMed     Text format     Abstract available


  35. ANNIBALI O, Hohaus S, Marchesi F, Cantonetti M, et al
    The neutrophil/lymphocyte ratio >/=3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network 'Rete Ematologica del Lazio per i Linfomi' (RELLI).
    Leuk Lymphoma. 2019 Jul 1:1-9. doi: 10.1080/10428194.2019.1633628.
    PubMed     Text format     Abstract available


    June 2019
  36. HILAL T, Maguire A, Kosiorek HE, Rimsza LM, et al
    Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma.
    Leuk Lymphoma. 2019 Jun 27:1-3. doi: 10.1080/10428194.2019.1633637.
    PubMed     Text format    


  37. ANDRAOS TY, Ayoub Z, Nastoupil LJ, Milgrom SA, et al
    Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma.
    Leuk Lymphoma. 2019 Jun 24:1-8. doi: 10.1080/10428194.2019.1627535.
    PubMed     Text format     Abstract available


  38. BAUES C, Gorgen H, Semrau R, Nast-Kolb B, et al
    Volumetric assessment of mediastinal lymphoma masses in Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Jun 22:1-7. doi: 10.1080/10428194.2019.1623888.
    PubMed     Text format     Abstract available


  39. BEHDAD A, Boddy CS, Fought AJ, Taxter T, et al
    Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status.
    Leuk Lymphoma. 2019 Jun 21:1-6. doi: 10.1080/10428194.2019.1622099.
    PubMed     Text format     Abstract available


  40. PERSONETT HA, Barreto EF, McCullough KB, Dierkhising R, et al
    Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
    Leuk Lymphoma. 2019 Jun 21:1-7. doi: 10.1080/10428194.2019.1574000.
    PubMed     Text format     Abstract available


  41. ZHONG C, Gragert L, Maiers M, Hill BT, et al
    The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population.
    Leuk Lymphoma. 2019 Jun 19:1-10. doi: 10.1080/10428194.2019.1617858.
    PubMed     Text format     Abstract available


  42. ACUNA-VILLAORDUNA A, Gonzalez-Lugo J, Ye BH, Adrianzen Herrera DA, et al
    High prevalence of pulmonary findings in computed tomographies of HTLV-1-infected patients with and without adult-T cell leukemia/lymphoma - implications for staging.
    Leuk Lymphoma. 2019 Jun 17:1-5. doi: 10.1080/10428194.2019.1627543.
    PubMed     Text format     Abstract available


  43. TOBIASSON M, Pandzic T, Cavelier L, Sander B, et al
    Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission.
    Leuk Lymphoma. 2019 Jun 17:1-4. doi: 10.1080/10428194.2019.1627541.
    PubMed     Text format    


  44. MILJKOVIC MD, Roschewski M, Dunleavy K, Wilson WH, et al
    Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Jun 17:1-4. doi: 10.1080/10428194.2019.1627540.
    PubMed     Text format    


  45. SHAW J, Harvey C, Richards C, Kim C, et al
    Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database.
    Leuk Lymphoma. 2019 Jun 12:1-9. doi: 10.1080/10428194.2019.1623886.
    PubMed     Text format     Abstract available


  46. SETHI TK, Kovach AE, Grover NS, Huang LC, et al
    Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.
    Leuk Lymphoma. 2019 Jun 11:1-10. doi: 10.1080/10428194.2019.1620942.
    PubMed     Text format     Abstract available


  47. MA H, Bhagat G, O'Connor OA
    A peripheral T-cell lymphoma (PTCL) arising as a post-transplant lymphoproliferative disorder: efficacy of pralatrexate in primary refractory disease and review of the literature.
    Leuk Lymphoma. 2019 Jun 11:1-4. doi: 10.1080/10428194.2019.1622102.
    PubMed     Text format    


  48. VASSEUR L, Lara D, Clappier E, Gillebert Q, et al
    Common clonal origin of an EBV-positive diffuse large B cell lymphoma and a chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2019 Jun 11:1-3. doi: 10.1080/10428194.2019.1627539.
    PubMed     Text format    


  49. PARK BB, Kim WS, Suh C, Hong JY, et al
    A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial).
    Leuk Lymphoma. 2019 Jun 6:1-7. doi: 10.1080/10428194.2019.1622100.
    PubMed     Text format     Abstract available


  50. PALMARSDOTTIR R, Kiesbye Ovlisen A, Tang Severinsen M, Glimelius I, et al
    Socioeconomic impact of Hodgkin lymphoma in adult patients: a systematic literature review.
    Leuk Lymphoma. 2019 Jun 6:1-16. doi: 10.1080/10428194.2019.1613538.
    PubMed     Text format     Abstract available


  51. ABADI U, Peled L, Gurion R, Rotman-Pikielny P, et al
    Prevalence and clinical significance of hypercalcemia at diagnosis in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Jun 6:1-5. doi: 10.1080/10428194.2019.1620946.
    PubMed     Text format     Abstract available


  52. ELMAAGACLI AH, Salwender H, Jehn C, Dahmash F, et al
    Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia - a prominent biomarker and potential target for anti-SLAMF7 antibody therapy.
    Leuk Lymphoma. 2019 Jun 4:1-4. doi: 10.1080/10428194.2019.1623887.
    PubMed     Text format    


    May 2019
  53. DINH A, Palmer MB, Svoboda J, Hogan JJ, et al
    Lenalidomide-induced tubulointerstitial nephritis in Hodgkin lymphoma.
    Leuk Lymphoma. 2019 May 24:1-3. doi: 10.1080/10428194.2019.1616187.
    PubMed     Text format    


  54. MARTIN P, Ruan J, Furman R, Rutherford S, et al
    A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.
    Leuk Lymphoma. 2019 May 23:1-5. doi: 10.1080/10428194.2019.1612062.
    PubMed     Text format     Abstract available


  55. FOSS FM, Parker TL, Girardi M, Li A, et al
    Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate.
    Leuk Lymphoma. 2019 May 23:1-4. doi: 10.1080/10428194.2019.1612061.
    PubMed     Text format     Abstract available


  56. BEST S, Liu T, Bruss N, Kittai A, et al
    Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
    Leuk Lymphoma. 2019 May 21:1-5. doi: 10.1080/10428194.2019.1616190.
    PubMed     Text format     Abstract available


  57. RUTHERFORD SC
    PET beyond Deauville in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 May 20:1-2. doi: 10.1080/10428194.2019.1599115.
    PubMed     Text format    


  58. SHIMAZU Y, Nohgawa M
    Plasma exchange following mogamulizumab therapy before bone marrow transplantation in refractory adult T-cell leukemia-lymphoma.
    Leuk Lymphoma. 2019 May 20:1-2. doi: 10.1080/10428194.2019.1616188.
    PubMed     Text format    


  59. PING N, Qu C, Bai L, Kang L, et al
    Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.
    Leuk Lymphoma. 2019 May 14:1-3. doi: 10.1080/10428194.2019.1605507.
    PubMed     Text format    


  60. HORGAN C, Elmoamly S, McIlroy G, Davies D, et al
    Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experience.
    Leuk Lymphoma. 2019 May 13:1-3. doi: 10.1080/10428194.2019.1607323.
    PubMed     Text format    


  61. QI SN, Xu LM, Yuan ZY, Wu T, et al
    Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG).
    Leuk Lymphoma. 2019 May 7:1-10. doi: 10.1080/10428194.2019.1602265.
    PubMed     Text format     Abstract available


  62. FERREIRA GA, Thome CH, Simao AMS, Scheucher PS, et al
    The lipid raft protein NTAL participates in AKT signaling in mantle cell lymphoma.
    Leuk Lymphoma. 2019 May 7:1-11. doi: 10.1080/10428194.2019.1607326.
    PubMed     Text format     Abstract available


  63. JAKOBSEN LH, Biccler JL, Brown PN, Jorgensen JM, et al
    No differential overall or relative survival effect of rituximab in male and female patients with diffuse large B-cell lymphoma: a Danish population-based study of 3783 patients.
    Leuk Lymphoma. 2019 May 6:1-4. doi: 10.1080/10428194.2019.1602264.
    PubMed     Text format    


  64. MOLETI ML, Al-Jadiry MF, Shateh WA, Al-Darraji AF, et al
    Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients.
    Leuk Lymphoma. 2019;60:1224-1233.
    PubMed     Text format     Abstract available


    April 2019
  65. ROBAK T, Smolewski P, Robak P, Dreyling M, et al
    Mantle cell lymphoma: therapeutic options in transplant-ineligible patients.
    Leuk Lymphoma. 2019 Apr 25:1-13. doi: 10.1080/10428194.2019.1605511.
    PubMed     Text format     Abstract available


  66. SUN M, Su W, Qian J, Meng H, et al
    The prognostic value of toll-like receptor5 and programmed cell death-ligand1 in patients with peripheral T-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Apr 24:1-12. doi: 10.1080/10428194.2019.1602266.
    PubMed     Text format     Abstract available


  67. GREENBAUM U, Levi I, Madmoni O, Lior Y, et al
    The prognostic significance of bone marrow involvement in diffuse large B cell lymphoma according to the flow cytometry.
    Leuk Lymphoma. 2019 Apr 24:1-6. doi: 10.1080/10428194.2019.1587755.
    PubMed     Text format     Abstract available


  68. VON TRESCKOW B, Fanale M, Ardeshna KM, Chen R, et al
    Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Apr 23:1-7. doi: 10.1080/10428194.2019.1602262.
    PubMed     Text format     Abstract available


  69. VIJENTHIRA A, Maganti M, Kukreti V, Kuruvilla J, et al
    Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naive patients.
    Leuk Lymphoma. 2019 Apr 18:1-4. doi: 10.1080/10428194.2019.1585837.
    PubMed     Text format    


  70. KEANE C, Yoon Cheah C
    Designing optimal prognostic models for diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Apr 16:1-3. doi: 10.1080/10428194.2019.1599117.
    PubMed     Text format    


  71. JURCZAK W, M Gruszka A, Sowa Staszczak A, Dlugosz-Danecka M, et al
    Consolidation with (90)Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up.
    Leuk Lymphoma. 2019 Apr 9:1-8. doi: 10.1080/10428194.2019.1602261.
    PubMed     Text format     Abstract available


  72. UMINO K, Fujiwara SI, Ikeda T, Kawaguchi SI, et al
    Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Apr 5:1-8. doi: 10.1080/10428194.2018.1564824.
    PubMed     Text format     Abstract available


  73. LIU J, Hong J, Ahn KS, Go J, et al
    ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines.
    Leuk Lymphoma. 2019 Apr 5:1-9. doi: 10.1080/10428194.2019.1594211.
    PubMed     Text format     Abstract available


  74. BICCLER JL, Savage KJ, Brown PDN, Jorgensen J, et al
    Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma.
    Leuk Lymphoma. 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594219.
    PubMed     Text format     Abstract available


  75. AYOUB Z, Andraos T, Milgrom SA, Pinnix CC, et al
    Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy.
    Leuk Lymphoma. 2019 Apr 3:1-9. doi: 10.1080/10428194.2019.1597081.
    PubMed     Text format     Abstract available


  76. SORIGUE M, Bishton M, Domingo-Domenech E, McMillan A, et al
    Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma.
    Leuk Lymphoma. 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594212.
    PubMed     Text format     Abstract available


    March 2019
  77. CHO SK, McCombs J, Punwani N, Lam J, et al
    Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States.
    Leuk Lymphoma. 2019 Mar 8:1-7. doi: 10.1080/10428194.2019.1581932.
    PubMed     Text format     Abstract available


  78. GOPALSAMY SN, Rosenthal KM, Ayers AA, Goy A, et al
    Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma.
    Leuk Lymphoma. 2019 Mar 8:1-9. doi: 10.1080/10428194.2019.1574006.
    PubMed     Text format     Abstract available


  79. JANTUNEN E, Varmavuo V, Pelkonen J, Valtola J, et al
    Importance of early immune recovery after autologous hematopoietic cell transplantation in lymphoma patients.
    Leuk Lymphoma. 2019 Mar 7:1-7. doi: 10.1080/10428194.2019.1581929.
    PubMed     Text format     Abstract available


  80. HARRINGTON BK, Wheeler E, Hornbuckle K, Y Shana'ah A, et al
    Modulation of immune checkpoint molecule expression in mantle cell lymphoma.
    Leuk Lymphoma. 2019 Mar 1:1-10. doi: 10.1080/10428194.2019.1569231.
    PubMed     Text format     Abstract available


  81. BROCCOLI A, Forti Parri SN, Pellegrini C, Casadei B, et al
    Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients.
    Leuk Lymphoma. 2019 Mar 1:1-8. doi: 10.1080/10428194.2019.1581931.
    PubMed     Text format     Abstract available


    February 2019
  82. SHIN SH, Kim YJ, Lee D, Cho D, et al
    Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes.
    Leuk Lymphoma. 2019 Feb 18:1-10. doi: 10.1080/10428194.2019.1573998.
    PubMed     Text format     Abstract available


  83. PHILLIPS EH, Devereux S, Radford J, Mir N, et al
    Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.
    Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1576870.
    PubMed     Text format    


  84. MARTIN P
    The optimal chemotherapy regimen for primary mediastinal B-cell lymphoma: we may never know.
    Leuk Lymphoma. 2019 Feb 8:1-2. doi: 10.1080/10428194.2018.1535119.
    PubMed     Text format    


  85. OKA S, Ono K, Nohgawa M
    Successful treatment with mogamulizumab of refractory/relapsed angioimmunoblastic T-cell lymphoma following autologous stem cell transplantation.
    Leuk Lymphoma. 2019 Feb 8:1-3. doi: 10.1080/10428194.2018.1537489.
    PubMed     Text format    


  86. PHILIP J, Collins A, Ritchie D, Le B, et al
    Patterns of end-of-life hospital care for patients with non-Hodgkin lymphoma: exploring the landscape.
    Leuk Lymphoma. 2019 Feb 7:1-9. doi: 10.1080/10428194.2018.1564047.
    PubMed     Text format     Abstract available


  87. LEPIK KV, Mikhailova NB, Moiseev IS, Kondakova EV, et al
    Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naive patients.
    Leuk Lymphoma. 2019 Feb 4:1-4. doi: 10.1080/10428194.2019.1573368.
    PubMed     Text format    


    January 2019
  88. SALLES GA, Pettengell R, Cordoba R, Dlugosz-Danecka M, et al
    Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review.
    Leuk Lymphoma. 2019 Jan 31:1-16. doi: 10.1080/10428194.2018.1564828.
    PubMed     Text format     Abstract available


  89. KAHL BS, Dreyling M, Gordon LI, Martin P, et al
    Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.
    Leuk Lymphoma. 2019 Jan 30:1-13. doi: 10.1080/10428194.2019.1571205.
    PubMed     Text format     Abstract available


  90. MARCHESELLI R, Franceschetto A, Sacchi S, Bari A, et al
    The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis.
    Leuk Lymphoma. 2019 Jan 28:1-7. doi: 10.1080/10428194.2018.1564049.
    PubMed     Text format     Abstract available


  91. GOLDSCHMIDT N, Horowitz NA, Hefetz V, Darawshy F, et al
    Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
    Leuk Lymphoma. 2019 Jan 28:1-9. doi: 10.1080/10428194.2018.1564823.
    PubMed     Text format     Abstract available


  92. WANG J, Van Den Berg D, Hwang AE, Weisenberger D, et al
    DNA methylation patterns of adult survivors of adolescent/young adult Hodgkin lymphoma compared to their unaffected monozygotic twin.
    Leuk Lymphoma. 2019 Jan 22:1-9. doi: 10.1080/10428194.2018.1533128.
    PubMed     Text format     Abstract available


  93. CLAUSEN MR, Ulrichsen SP, Larsen TS, Poulsen CB, et al
    Depth of neutrophil nadir after first cycle of R-CHOP predicts outcome in diffuse large B-cell lymphoma - a nationwide population-based cohort study.
    Leuk Lymphoma. 2019 Jan 22:1-8. doi: 10.1080/10428194.2018.1554863.
    PubMed     Text format     Abstract available


  94. MESSMER M, Tsai HL, Varadhan R, Swinnen LJ, et al
    R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma.
    Leuk Lymphoma. 2019 Jan 18:1-5. doi: 10.1080/10428194.2018.1519812.
    PubMed     Text format     Abstract available


  95. NEVEL KS, Pentsova E, Daras M
    Clinical presentation, treatment, and outcomes of patients with central nervous system involvement in extranodal natural killer/T-cell lymphoma.
    Leuk Lymphoma. 2019 Jan 16:1-8. doi: 10.1080/10428194.2018.1551541.
    PubMed     Text format     Abstract available


  96. PATHAK P, Perimbeti S, Ames A, Moskowitz AJ, et al
    Guillain Barre syndrome heralding the diagnosis of angioimmunoblastic T-cell lymphoma.
    Leuk Lymphoma. 2019 Jan 16:1-4. doi: 10.1080/10428194.2018.1553299.
    PubMed     Text format    


  97. WANG XX, Li PF, Bai B, Gao Y, et al
    Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
    Leuk Lymphoma. 2019 Jan 16:1-9. doi: 10.1080/10428194.2018.1563690.
    PubMed     Text format     Abstract available


  98. CHEN SH, Chen JS, Jou ST, Wu KH, et al
    Outcome and prognosis of anaplastic large cell lymphoma in children: a report from the Taiwan Pediatric Oncology Group.
    Leuk Lymphoma. 2019 Jan 15:1-8. doi: 10.1080/10428194.2018.1562182.
    PubMed     Text format     Abstract available


  99. ANSELL SM
    Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture?
    Leuk Lymphoma. 2019 Jan 11:1-2. doi: 10.1080/10428194.2018.1543887.
    PubMed     Text format    


  100. GUZAUSKAS GF, Masaquel A, Thuresson PO, Dawson K, et al
    Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.
    Leuk Lymphoma. 2019 Jan 11:1-9. doi: 10.1080/10428194.2018.1551532.
    PubMed     Text format     Abstract available


  101. BOHN JP, Willenbacher W, Haas G, Peschel I, et al
    Pomalidomide in primary intraocular lymphoma.
    Leuk Lymphoma. 2019 Jan 11:1-3. doi: 10.1080/10428194.2018.1538508.
    PubMed     Text format    


  102. RITTER AJ, Goldstein JS, Ayers AA, Flowers CR, et al
    Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study.
    Leuk Lymphoma. 2019 Jan 11:1-12. doi: 10.1080/10428194.2018.1546855.
    PubMed     Text format     Abstract available


  103. AL-MANSOUR Z, Li H, Cook JR, Constine LS, et al
    Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.
    Leuk Lymphoma. 2019 Jan 10:1-8. doi: 10.1080/10428194.2018.1563691.
    PubMed     Text format     Abstract available


  104. MARECKOVA A, Malcikova J, Tom N, Pal K, et al
    ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
    Leuk Lymphoma. 2019 Jan 10:1-9. doi: 10.1080/10428194.2018.1542144.
    PubMed     Text format     Abstract available


    December 2018
  105. HAPGOOD G, Stone JM, Zannino D, George A, et al
    A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Dec 14:1-8. doi: 10.1080/10428194.2018.1516873.
    PubMed     Text format     Abstract available


  106. RUEDA A, Calvo V, Casanova M, Rodriguez-Abreu D, et al
    Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
    Leuk Lymphoma. 2018 Dec 5:1-4. doi: 10.1080/10428194.2018.1542147.
    PubMed     Text format    


  107. STEVENSON JKR, Qiao Y, Chan KKW, Beca J, et al
    Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent.
    Leuk Lymphoma. 2018 Dec 5:1-9. doi: 10.1080/10428194.2018.1538509.
    PubMed     Text format     Abstract available


  108. KREISSL S, Goergen H, Muller H, Meissner J, et al
    Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.
    Leuk Lymphoma. 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1540781.
    PubMed     Text format     Abstract available


  109. MAJOR A, Jackson MW, Smith DE, Kamdar M, et al
    Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis.
    Leuk Lymphoma. 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1522435.
    PubMed     Text format     Abstract available


    November 2018
  110. TSENG YD, Ng AK, Wirth A
    New tools of the trade: parsing out the role of radiotherapy for early-stage diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Nov 27:1-3. doi: 10.1080/10428194.2018.1531397.
    PubMed     Text format    


  111. SUN Y, Murty VV, Leeman-Neill R, Soderquist C, et al
    Cytogenetic analysis of adult T-Cell leukemia/lymphoma: evaluation of a Caribbean cohort.
    Leuk Lymphoma. 2018 Nov 27:1-3. doi: 10.1080/10428194.2018.1538506.
    PubMed     Text format    


  112. ITO Y, Umezu T, Tadokoro K, Saito Y, et al
    BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma.
    Leuk Lymphoma. 2018 Nov 27:1-6. doi: 10.1080/10428194.2018.1529310.
    PubMed     Text format     Abstract available


  113. GRASS GD, Mills MN, Ahmed KA, Liveringhouse CL, et al
    Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations.
    Leuk Lymphoma. 2018 Nov 20:1-8. doi: 10.1080/10428194.2018.1506586.
    PubMed     Text format     Abstract available


  114. CHATURVEDI NK, Hatch ND, Sutton GL, Kling M, et al
    A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib.
    Leuk Lymphoma. 2018 Nov 14:1-10. doi: 10.1080/10428194.2018.1520986.
    PubMed     Text format     Abstract available


  115. ZAJAC-SPYCHALA O, Wachowiak J, Szmydki-Baran A, Hutnik L, et al
    Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology.
    Leuk Lymphoma. 2018 Nov 5:1-9. doi: 10.1080/10428194.2018.1466293.
    PubMed     Text format     Abstract available


    October 2018
  116. TANG R, Su C, Bai HX, Zeng Z, et al
    Association of insurance status with survival in patients with cutaneous T-cell lymphoma.
    Leuk Lymphoma. 2018 Oct 16:1-8. doi: 10.1080/10428194.2018.1520987.
    PubMed     Text format     Abstract available


  117. ZINZANI PL, Santoro A, Chiti A, Lastoria S, et al
    Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Oct 15:1-10. doi: 10.1080/10428194.2018.1519808.
    PubMed     Text format     Abstract available


  118. BAPTISTA MJ, Tapia G, Morgades M, Muncunill J, et al
    Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Oct 15:1-5. doi: 10.1080/10428194.2018.1512711.
    PubMed     Text format    


  119. FARRUGGIA P, Puccio G, Locatelli F, Vetro M, et al
    Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience.
    Leuk Lymphoma. 2018 Oct 10:1-7. doi: 10.1080/10428194.2018.1493732.
    PubMed     Text format     Abstract available


  120. REIMAN T, Savage KJ, Crump M, Cheung MC, et al
    A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 studydagger.
    Leuk Lymphoma. 2018 Oct 10:1-8. doi: 10.1080/10428194.2018.1515937.
    PubMed     Text format     Abstract available


  121. LE CLEF Q, Ortega-Sanchez G, Dirnhofer S, Tzankov A, et al
    T-lymphoblastic lymphoma after previous thymoma: how NGS helps establishing the diagnosis and procures new insights.
    Leuk Lymphoma. 2018 Oct 10:1-4. doi: 10.1080/10428194.2018.1520993.
    PubMed     Text format    


  122. WU X, Hsu DK, Wang KH, Huang Y, et al
    IL-10 is overexpressed in human cutaneous T-cell lymphoma and is required for maximal tumor growth in a mouse model.
    Leuk Lymphoma. 2018 Oct 2:1-9. doi: 10.1080/10428194.2018.1516037.
    PubMed     Text format     Abstract available


  123. ANDERSEN MD, Kamper P, d'Amore A, Clausen M, et al
    The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor (dagger).
    Leuk Lymphoma. 2018 Oct 2:1-7. doi: 10.1080/10428194.2018.1515939.
    PubMed     Text format     Abstract available


  124. BADAR T, Hamadani M, Bachanova V, Maddocks KJ, et al
    Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.
    Leuk Lymphoma. 2018 Oct 2:1-7. doi: 10.1080/10428194.2018.1515944.
    PubMed     Text format     Abstract available


  125. LIU YZ, Xue K, Wang BS, Li CY, et al
    The size and depth of lesions measured by endoscopic ultrasonography are novel prognostic factors of primary gastric diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Oct 2:1-6. doi: 10.1080/10428194.2018.1515942.
    PubMed     Text format     Abstract available


  126. CHEN YF, Chang CH, Huang ZN, Su YC, et al
    The JAK inhibitor antcin H exhibits direct anticancer activity while enhancing chemotherapy against LMP1-expressed lymphoma.
    Leuk Lymphoma. 2018 Oct 2:1-11. doi: 10.1080/10428194.2018.1512709.
    PubMed     Text format     Abstract available


  127. SHARMAN JP, Forero-Torres A, Costa LJ, Flinn IW, et al
    Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1515940.
    PubMed     Text format     Abstract available


  128. GOYAL RK, Nagar SP, Kabadi SM, Kaye JA, et al
    Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States.
    Leuk Lymphoma. 2018 Oct 2:1-9. doi: 10.1080/10428194.2018.1509320.
    PubMed     Text format     Abstract available


  129. DHEUR MS, Poirel HA, Ameye G, Tilman G, et al
    Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1508663.
    PubMed     Text format     Abstract available


    September 2018
  130. SHAO C, Liu J, Zhou W, Raut MK, et al
    Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin.
    Leuk Lymphoma. 2018 Sep 20:1-8. doi: 10.1080/10428194.2018.1508665.
    PubMed     Text format     Abstract available


  131. CAMUS V, Dubois S, Jardin F, Tilly H, et al
    Prognostic impact of diagnosis to treatment interval (DTI) in diffuse large B-cell lymphoma patients: a real-life monocentric study.
    Leuk Lymphoma. 2018 Sep 20:1-3. doi: 10.1080/10428194.2018.1508671.
    PubMed     Text format    


  132. PROVENCIO M, Franco F, Gomez-Codina J, Quero Blanco C, et al
    Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years.
    Leuk Lymphoma. 2018 Sep 20:1-4. doi: 10.1080/10428194.2018.1509322.
    PubMed     Text format    


  133. CENCINI E, Fabbri A, Schiattone L, Bocchia M, et al
    Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma.
    Leuk Lymphoma. 2018 Sep 20:1-3. doi: 10.1080/10428194.2018.1504938.
    PubMed     Text format    


  134. UMINO K, Fujiwara SI, Minakata D, Yamamoto C, et al
    Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Leuk Lymphoma. 2018 Sep 6:1-8. doi: 10.1080/10428194.2018.1504939.
    PubMed     Text format     Abstract available


  135. GANZEL C, Silverman B, Chemtob D, Ben Shoham A, et al
    The risk of tuberculosis in cancer patients is greatest in lymphoma and myelodysplastic syndrome/myeloproliferative neoplasm: a large population-based cohort study.
    Leuk Lymphoma. 2018 Sep 6:1-6. doi: 10.1080/10428194.2018.1499904.
    PubMed     Text format     Abstract available


  136. OBR A, Prochazka V, Papajik T, Klener P Jr, et al
    Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry(dagger).
    Leuk Lymphoma. 2018 Sep 6:1-8. doi: 10.1080/10428194.2018.1508672.
    PubMed     Text format     Abstract available


  137. CICHOWSKA-CWALINSKA N, Dutka M, Klapkowski A, Peksa R, et al
    The role of radiotherapy in the management of primary cardiac lymphoma a case report and the literature review.
    Leuk Lymphoma. 2018 Sep 6:1-5. doi: 10.1080/10428194.2018.1509321.
    PubMed     Text format    


  138. ISE M, Kageyama H, Araki A, Itami M, et al
    Identification of a novel GORASP2-ALK fusion in an ALK-positive large B-cell lymphoma.
    Leuk Lymphoma. 2018 Sep 6:1-5. doi: 10.1080/10428194.2018.1493731.
    PubMed     Text format    


  139. OHNO H, Nakagawa M, Kishimori C, Fukutsuka K, et al
    A rare MYC/BCL3 double-translocation and protein-expression in a diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Sep 6:1-4. doi: 10.1080/10428194.2018.1498493.
    PubMed     Text format    


  140. ROTOLO A, Karadimitris A, Ruella M
    Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.
    Leuk Lymphoma. 2018;59:2040-2055.
    PubMed     Text format     Abstract available


    August 2018
  141. WALEWSKI J, Paszkiewicz-Kozik E, Borsaru G, Hellmann A, et al
    Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
    Leuk Lymphoma. 2018 Aug 30:1-10. doi: 10.1080/10428194.2018.1492122.
    PubMed     Text format     Abstract available


  142. BESSI L, Viailly PJ, Bohers E, Ruminy P, et al
    Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Aug 2:1-5. doi: 10.1080/10428194.2018.1492123.
    PubMed     Text format    


  143. ROBERTS ZJ, Better M, Bot A, Roberts MR, et al
    Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Leuk Lymphoma. 2018;59:1785-1796.
    PubMed     Text format     Abstract available


    July 2018
  144. QIN W, Yuan Q, Wu J, Yu H, et al
    Prognostic value of pre-therapy C-reactive protein level in diffuse large B-cell lymphoma: a meta-analysis.
    Leuk Lymphoma. 2018 Jul 22:1-9. doi: 10.1080/10428194.2018.1482540.
    PubMed     Text format     Abstract available


  145. BARP A, Gilardin L, Afanasiev V, Delorme C, et al
    Subacute inflammatory demyelinating polyradiculoneuropathy complicating relapsing Hodgkin lymphoma: another immune-related adverse event of the anti-PD1 therapy?
    Leuk Lymphoma. 2018 Jul 22:1-3. doi: 10.1080/10428194.2018.1485912.
    PubMed     Text format    


  146. AMBADY P, Szidonya L, Firkins J, James J, et al
    Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma.
    Leuk Lymphoma. 2018 Jul 22:1-4. doi: 10.1080/10428194.2018.1480771.
    PubMed     Text format    


  147. BRANDT A, Matschke J, Fehrle W, von Wenserski L, et al
    A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells.
    Leuk Lymphoma. 2018 Jul 22:1-7. doi: 10.1080/10428194.2018.1482538.
    PubMed     Text format     Abstract available


  148. CASTELLO A, Grizzi F, Qehajaj D, Rahal D, et al
    (18)F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors.
    Leuk Lymphoma. 2018 Jul 22:1-9. doi: 10.1080/10428194.2018.1488254.
    PubMed     Text format     Abstract available


  149. WROBEL T, Biecek P, Rybka J, Szulgo A, et al
    Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group().
    Leuk Lymphoma. 2018 Jul 6:1-8. doi: 10.1080/10428194.2018.1482539.
    PubMed     Text format     Abstract available


  150. LIM SW, Ryu KJ, Lee H, Ko YH, et al
    Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma.
    Leuk Lymphoma. 2018 Jul 6:1-9. doi: 10.1080/10428194.2018.1480772.
    PubMed     Text format     Abstract available


  151. TANEJA A, Jones J, Pittaluga S, Maric I, et al
    Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
    Leuk Lymphoma. 2018 Jul 6:1-4. doi: 10.1080/10428194.2018.1480775.
    PubMed     Text format    


  152. CHAEKAL OK, van Besien K
    A renaissance for autologous transplantation in follicular lymphoma?
    Leuk Lymphoma. 2018 Jul 3:1-3. doi: 10.1080/10428194.2018.1480777.
    PubMed     Text format    


  153. ALBANO D, Bosio G, Re A, Pagani C, et al
    Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt's lymphoma: the role of Deauville and IHP criteria.
    Leuk Lymphoma. 2018 Jul 3:1-8. doi: 10.1080/10428194.2018.1482541.
    PubMed     Text format     Abstract available


  154. PONTIKOGLOU C, Kalyva A, Kalpadakis C, Velegraki M, et al
    Bone marrow-derived mesenchymal stem/stromal cells from patients with splenic marginal zone lymphoma are intrinsically impaired and influence the malignant B-cells.
    Leuk Lymphoma. 2018 Jul 3:1-3. doi: 10.1080/10428194.2018.1474526.
    PubMed     Text format    


  155. OLLILA TA, Olszewski AJ
    Radiation therapy in primary testicular lymphoma: does practice match the standard of care?
    Leuk Lymphoma. 2018 Jul 3:1-4. doi: 10.1080/10428194.2018.1480776.
    PubMed     Text format    


  156. MANNA M, Lee-Ying R, Davies G, Stewart C, et al
    Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world.
    Leuk Lymphoma. 2018 Jul 3:1-9. doi: 10.1080/10428194.2018.1473576.
    PubMed     Text format     Abstract available


  157. CHAN H, Moraes FY, Berlin A, Crump M, et al
    Significance of treatment response when managing patients with primary central nervous system lymphoma.
    Leuk Lymphoma. 2018 Jul 3:1-9. doi: 10.1080/10428194.2018.1474524.
    PubMed     Text format     Abstract available


  158. HOSSAIN NM, Dahiya S, Le R, Abramian AM, et al
    Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.
    Leuk Lymphoma. 2018 Jul 3:1-4. doi: 10.1080/10428194.2018.1474463.
    PubMed     Text format    


  159. SANDOVAL-SUS JD, Faramand R, Chavez J, Puri S, et al
    Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study.
    Leuk Lymphoma. 2018 Jul 2:1-8. doi: 10.1080/10428194.2018.1468894.
    PubMed     Text format     Abstract available


  160. GULATI N, Beguelin W, Giulino-Roth L
    Enhancer of zeste homolog 2 (EZH2) inhibitors.
    Leuk Lymphoma. 2018;59:1574-1585.
    PubMed     Text format     Abstract available


  161. STRATI P, Tang G, Duose DY, Mallampati S, et al
    Myeloid/lymphoid neoplasms with FGFR1 rearrangement.
    Leuk Lymphoma. 2018;59:1672-1676.
    PubMed     Text format     Abstract available


    June 2018
  162. HUNTINGTON S, Keshishian A, McGuire M, Xie L, et al
    Costs of relapsed diffuse large B-cell lymphoma among Medicare patients.
    Leuk Lymphoma. 2018 Jun 25:1-8. doi: 10.1080/10428194.2018.1459613.
    PubMed     Text format     Abstract available


  163. LONTOS K, Tsagianni A, Yuan JM, Normolle DP, et al
    Location matters in early stage nodal diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Jun 22:1-4. doi: 10.1080/10428194.2018.1471600.
    PubMed     Text format    


  164. WALSHAW RC, Illidge TM
    Revisiting the role of radiotherapy in Hodgkin lymphoma to augment systemic immunity.
    Leuk Lymphoma. 2018 Jun 22:1-2. doi: 10.1080/10428194.2018.1464160.
    PubMed     Text format    


  165. AGARWAL R, Dawson MA, Dreyling M, Tam CS, et al
    Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
    Leuk Lymphoma. 2018 Jun 18:1-13. doi: 10.1080/10428194.2018.1457148.
    PubMed     Text format     Abstract available


  166. CALZADA O, Switchenko JM, Maly JJ, Blum KA, et al
    Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma.
    Leuk Lymphoma. 2018 Jun 18:1-9. doi: 10.1080/10428194.2018.1455973.
    PubMed     Text format     Abstract available


  167. HONG H, Fang X, Wang Z, Huang H, et al
    Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study.
    Leuk Lymphoma. 2018 Jun 18:1-6. doi: 10.1080/10428194.2018.1459610.
    PubMed     Text format     Abstract available


  168. ROSWARSKI J, Roschewski M, Lucas A, Melani C, et al
    Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.
    Leuk Lymphoma. 2018;59:1466-1469.
    PubMed     Text format    


    May 2018
  169. REICH-SLOTKY R, Makhani SS, Vasovic LV, Pearse RN, et al
    Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products.
    Leuk Lymphoma. 2018 May 23:1-7. doi: 10.1080/10428194.2018.1455975.
    PubMed     Text format     Abstract available


  170. SETHI TK, Reddy NM
    Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies.
    Leuk Lymphoma. 2018 May 9:1-13. doi: 10.1080/10428194.2018.1466296.
    PubMed     Text format     Abstract available


  171. LICATA MJ, Janakiram M, Tan S, Fang Y, et al
    Diagnostic challenges of adult T-cell leukemia/lymphoma in North America - a clinical, histological, and immunophenotypic correlation with a workflow proposal.
    Leuk Lymphoma. 2018;59:1188-1194.
    PubMed     Text format     Abstract available


  172. SPINA F, Radice T, De Philippis C, Soldarini M, et al
    Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival.
    Leuk Lymphoma. 2018 May 1:1-9. doi: 10.1080/10428194.2018.1459607.
    PubMed     Text format     Abstract available


  173. FRICK M, Bettstetter M, Bertz S, Schwarz-Furlan S, et al
    Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.
    Leuk Lymphoma. 2018;59:1260-1263.
    PubMed     Text format    


    April 2018
  174. LUDMIR EB, Milgrom SA, Pinnix CC, Gunther JR, et al
    Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure().
    Leuk Lymphoma. 2018 Apr 26:1-8. doi: 10.1080/10428194.2018.1460825.
    PubMed     Text format     Abstract available


  175. NANNI L, Broccoli A, Nanni C, Argnani L, et al
    Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1443336.
    PubMed     Text format    


  176. BEYGI S, Sadashiv S, Reilly JB, Khan C, et al
    Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era.
    Leuk Lymphoma. 2018 Apr 4:1-15. doi: 10.1080/10428194.2018.1443332.
    PubMed     Text format     Abstract available


  177. ZAJA F, Salvi F, Rossi M, Sabattini E, et al
    Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.
    Leuk Lymphoma. 2018 Apr 4:1-7. doi: 10.1080/10428194.2018.1452208.
    PubMed     Text format     Abstract available


  178. PINNIX CC, Wirth A, Milgrom SA, Andraos TY, et al
    Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy.
    Leuk Lymphoma. 2018 Apr 4:1-10. doi: 10.1080/10428194.2018.1452211.
    PubMed     Text format     Abstract available


  179. VIDAL L, Lando S, Vaxman I, Shochat T, et al
    The effect of R-CHOP dose reduction on overall survival of elderly patients with DLBCL - comparative study.
    Leuk Lymphoma. 2018;59:904-910.
    PubMed     Text format     Abstract available


  180. CASTANEDA C, Minton N, Mezo M, Hirsch D, et al
    False-positive pregnancy tests in females of reproductive potential receiving lenalidomide in the United States.
    Leuk Lymphoma. 2018;59:1025-1026.
    PubMed     Text format    


  181. SCHAFFER M, Chaturvedi S, Davis C, Aquino R, et al
    Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.
    Leuk Lymphoma. 2018;59:931-940.
    PubMed     Text format     Abstract available


    March 2018
  182. WIGHT JC, Hawkes EA, Berlangieri SU, Khor R, et al
    An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Mar 23:1-3. doi: 10.1080/10428194.2018.1452217.
    PubMed     Text format    


  183. ZHANG PP, Ding DZ, Shi B, Zhang SQ, et al
    Expression of TRIM28 correlates with proliferation and Bortezomib-induced apoptosis in B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Mar 23:1-11. doi: 10.1080/10428194.2018.1452207.
    PubMed     Text format     Abstract available


  184. DHOLARIA BR, Hammond WA, Roy V, Sher T, et al
    Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience.
    Leuk Lymphoma. 2018 Mar 23:1-4. doi: 10.1080/10428194.2018.1452220.
    PubMed     Text format    


  185. SORIGUE M, Orna E, Sancho JM
    Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
    Leuk Lymphoma. 2018 Mar 21:1-10. doi: 10.1080/10428194.2018.1448085.
    PubMed     Text format     Abstract available


  186. JANIGA J, Kentley J, Nabhan C, Abdulla F, et al
    Current systemic therapeutic options for advanced mycosis fungoides and Sezary syndrome.
    Leuk Lymphoma. 2018;59:562-577.
    PubMed     Text format     Abstract available


    February 2018
  187. FEUGIER P, Brice P, Maynadie M, Franchi-Rezgui P, et al
    Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study.
    Leuk Lymphoma. 2018 Feb 28:1-4. doi: 10.1080/10428194.2018.1434878.
    PubMed     Text format    


  188. PEIL-GRUN A, Trenker C, Gorg K, Neesse A, et al
    Diagnostic accuracy and interobserver agreement of contrast-enhanced ultrasound in the evaluation of residual lesions after treatment for malignant lymphoma and testicular cancer: a retrospective pilot study in 52 patients().
    Leuk Lymphoma. 2018 Feb 27:1-6. doi: 10.1080/10428194.2018.1439170.
    PubMed     Text format     Abstract available


  189. DE LUCA G, Trasarti S, Bizzoni L, Del Giudice I, et al
    Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders.
    Leuk Lymphoma. 2018 Feb 23:1-4. doi: 10.1080/10428194.2018.1439583.
    PubMed     Text format    


  190. CASEY N, Fujiwara H, Azuma T, Murakami Y, et al
    An unusual, CD4 and CD8 dual-positive, CD25 negative, tumor cell phenotype in a patient with adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1439168.
    PubMed     Text format    


  191. HAN W, Ibarra G, Gupta M, Yin Y, et al
    Elevated GLI3 expression in germinal center diffuse large B cell lymphoma.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1439169.
    PubMed     Text format    


  192. BURNELLI R, Rinieri S, Rondelli R, Todesco A, et al
    Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy.
    Leuk Lymphoma. 2018 Feb 16:1-10. doi: 10.1080/10428194.2018.1435872.
    PubMed     Text format     Abstract available


  193. STECCO A, Buemi F, Iannessi A, Carriero A, et al
    Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma.
    Leuk Lymphoma. 2018 Feb 12:1-11. doi: 10.1080/10428194.2018.1434881.
    PubMed     Text format     Abstract available


  194. MARRERO WD, Cruz-Chacon A, Cabanillas F
    Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant?
    Leuk Lymphoma. 2018 Feb 7:1-3. doi: 10.1080/10428194.2018.1427863.
    PubMed     Text format    


  195. THORP BC, Badoux X
    Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Leuk Lymphoma. 2018;59:311-320.
    PubMed     Text format     Abstract available


  196. GOYAL S, Oak E, Luo J, Cashen AF, et al
    Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study.
    Leuk Lymphoma. 2018;59:357-362.
    PubMed     Text format     Abstract available


    January 2018
  197. VILLA D, Sehn LH
    Double hit lymphoma: do we need a 'double hit' of intensive therapy?
    Leuk Lymphoma. 2018 Jan 25:1-2. doi: 10.1080/10428194.2018.1429606.
    PubMed     Text format    


  198. PHIPPS C, Lee YS, Ying H, Nagarajan C, et al
    The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Jan 18:1-6. doi: 10.1080/10428194.2017.1422863.
    PubMed     Text format     Abstract available


  199. KOJIMA M, Carreras J, Kikuti YY, Miyaoka M, et al
    A case of diffuse large B-cell lymphoma with MYC gene cluster amplification related to chromothripsis.
    Leuk Lymphoma. 2018 Jan 18:1-5. doi: 10.1080/10428194.2017.1421753.
    PubMed     Text format    


  200. DRACH J, Huang H, Samoilova O, Belch A, et al
    Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the random
    Leuk Lymphoma. 2018 Jan 17:1-8. doi: 10.1080/10428194.2017.1365855.
    PubMed     Text format     Abstract available


  201. COLLINS GP, Rueda A, Salles G, von Tresckow B, et al
    Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.
    Leuk Lymphoma. 2018 Jan 16:1-8. doi: 10.1080/10428194.2017.1421762.
    PubMed     Text format     Abstract available


  202. SONBOL MB, Hilal T, Dueck AC, Rosenthal AC, et al
    A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.
    Leuk Lymphoma. 2018 Jan 10:1-7. doi: 10.1080/10428194.2017.1416368.
    PubMed     Text format     Abstract available


  203. DITTUS C, Grover N, Ellsworth S, Tan X, et al
    Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
    Leuk Lymphoma. 2018 Jan 5:1-7. doi: 10.1080/10428194.2017.1416365.
    PubMed     Text format     Abstract available


  204. CRAMER P, Fraser G, Santucci-Silva R, Grosicki S, et al
    Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in t
    Leuk Lymphoma. 2018 Jan 3:1-10. doi: 10.1080/10428194.2017.1416364.
    PubMed     Text format     Abstract available


  205. WEVER CM, Geoffrion D, Grande BM, Yu S, et al
    The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples.
    Leuk Lymphoma. 2018 Jan 3:1-16. doi: 10.1080/10428194.2017.1413186.
    PubMed     Text format     Abstract available


  206. TOMITA N, Yokoyama M, Yamamoto W, Watanabe R, et al
    The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis.
    Leuk Lymphoma. 2018;59:97-104.
    PubMed     Text format     Abstract available


  207. RUTHERFORD SC, Stewart EN, Chen Z, Chadburn A, et al
    The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data<sup/>.
    Leuk Lymphoma. 2018;59:256-258.
    PubMed     Text format    


  208. WEHKAMP U, Weichenthal M, Klapper W, Schwarz T, et al
    Unilesional locally recurrent lymphomatoid papulosis with variable histological presentation.
    Leuk Lymphoma. 2018;59:262-264.
    PubMed     Text format    


    December 2017
  209. LAMAR ZS, Dothard A, Kennedy L, Isom S, et al
    Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study.
    Leuk Lymphoma. 2017 Dec 18:1-7. doi: 10.1080/10428194.2017.1410889.
    PubMed     Text format     Abstract available


  210. ALJOHANI N, Choi SJ, Day AG, Alhejaily A, et al
    Abundant expression of BMI1 in follicular lymphoma is associated with reduced overall survival.
    Leuk Lymphoma. 2017 Dec 18:1-9. doi: 10.1080/10428194.2017.1410883.
    PubMed     Text format     Abstract available


  211. ARIMA H, Fujimoto M, Nishikori M, Kitano T, et al
    Prognostic impact of activation-induced cytidine deaminase expression for patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Dec 18:1-11. doi: 10.1080/10428194.2017.1410884.
    PubMed     Text format     Abstract available


  212. FU J, Upshaw J, Cohen J, Rodday AM, et al
    Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review.
    Leuk Lymphoma. 2017 Dec 7:1-5. doi: 10.1080/10428194.2017.1406086.
    PubMed     Text format    


  213. SU C, Nguyen KA, Bai HX, Cao Y, et al
    Disease site as a determinant of survival outcome in patients with primary cutaneous peripheral T-cell lymphoma, unspecified: an analysis of 4057 cases from the US National Cancer Database.
    Leuk Lymphoma. 2017 Dec 7:1-8. doi: 10.1080/10428194.2017.1410886.
    PubMed     Text format     Abstract available


  214. BLOMBERY P, Lickiss J, Dickinson M
    The price of success-health economics of personalized diffuse large B-cell lymphoma treatment.
    Leuk Lymphoma. 2017 Dec 7:1-3. doi: 10.1080/10428194.2017.1408088.
    PubMed     Text format    


  215. CHEN AI, Leonard JT, Okada CY, Gay ND, et al
    Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
    Leuk Lymphoma. 2017 Dec 3:1-6. doi: 10.1080/10428194.2017.1406085.
    PubMed     Text format     Abstract available


  216. CHENG WY, Zhu YM, Cheng S, Chen YS, et al
    Development of B-cell prolymphocytic leukemia in a patient with splenic diffuse red pulp small B-cell lymphoma.
    Leuk Lymphoma. 2017 Dec 3:1-4. doi: 10.1080/10428194.2017.1405397.
    PubMed     Text format    


    November 2017
  217. GIULINO-ROTH L, O'Donohue T, Chen Z, Trippett TM, et al
    Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience.
    Leuk Lymphoma. 2017 Nov 29:1-10. doi: 10.1080/10428194.2017.1403601.
    PubMed     Text format     Abstract available


  218. DREYLING M, Aurer I, Cortelazzo S, Hermine O, et al
    Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.
    Leuk Lymphoma. 2017 Nov 27:1-15. doi: 10.1080/10428194.2017.1403602.
    PubMed     Text format     Abstract available


  219. SARID N, Sherban A, Bendet A, Adam S, et al
    CT findings are highly predictive for perforation in patients with diffuse large B-cell lymphoma involving the intestines.
    Leuk Lymphoma. 2017 Nov 27:1-6. doi: 10.1080/10428194.2017.1403023.
    PubMed     Text format     Abstract available


  220. KEMPIN S, Finger PT, Gale RP, Rescigno J, et al
    A cluster of vitreoretinal lymphoma in New York with possible link to the Chernobyl nuclear disaster.
    Leuk Lymphoma. 2017 Nov 22:1-4. doi: 10.1080/10428194.2017.1403025.
    PubMed     Text format    


  221. KO SH, Lee JH, Lee JH, Park HS, et al
    Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors.
    Leuk Lymphoma. 2017 Nov 22:1-11. doi: 10.1080/10428194.2017.1399310.
    PubMed     Text format     Abstract available


  222. BODY S, Esteve-Arenys A, Recasens-Zorzo C, Troussard X, et al
    A mouse model of disseminated mantle cell lymphoma highlights a lack of activity of estrogen receptor beta agonists toward tumor burden.
    Leuk Lymphoma. 2017 Nov 22:1-4. doi: 10.1080/10428194.2017.1399313.
    PubMed     Text format    


  223. TAN CRC, Barta SK, Lee J, Rudek MA, et al
    Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034.
    Leuk Lymphoma. 2017 Nov 21:1-10. doi: 10.1080/10428194.2017.1403597.
    PubMed     Text format     Abstract available


  224. GLEESON M, Peckitt C, Cunningham D, Gibb A, et al
    Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
    Leuk Lymphoma. 2017 Nov 9:1-10. doi: 10.1080/10428194.2017.1393671.
    PubMed     Text format     Abstract available


  225. MARTINEZ-TRILLOS A, Pinyol M, Delgado J, Aymerich M, et al
    The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Nov 8:1-9. doi: 10.1080/10428194.2017.1397660.
    PubMed     Text format     Abstract available


  226. NEUMANN DR, Marini BL, Phillips TJ, Wilcox RA, et al
    Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma.
    Leuk Lymphoma. 2017 Nov 6:1-10. doi: 10.1080/10428194.2017.1393672.
    PubMed     Text format     Abstract available


    October 2017
  227. GREIL C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, et al
    Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.
    Leuk Lymphoma. 2017 Oct 30:1-4. doi: 10.1080/10428194.2017.1393673.
    PubMed     Text format    


  228. ITOH K, Igarashi T, Irisawa H, Aotsuka N, et al
    Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).
    Leuk Lymphoma. 2017 Oct 30:1-8. doi: 10.1080/10428194.2017.1390233.
    PubMed     Text format     Abstract available


  229. BELTRAN BE, Quinones P, Sanchez G, Paredes A, et al
    Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?
    Leuk Lymphoma. 2017 Oct 30:1-3. doi: 10.1080/10428194.2017.1393666.
    PubMed     Text format    


  230. CHEN Q, Staton AD, Ayer T, Goldstein DA, et al
    Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Oct 25:1-10. doi: 10.1080/10428194.2017.1390230.
    PubMed     Text format     Abstract available


  231. ZAGADAILOV EA, Corman S, Chirikov V, Johnson C, et al
    Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1382698.
    PubMed     Text format     Abstract available


  232. JUSKEVICIUS D, Muller A, Hashwah H, Lundberg P, et al
    Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1387903.
    PubMed     Text format     Abstract available


  233. ZHANG C, Amos Burke GA
    Pediatric precursor B-cell acute lymphoblastic leukemia with MYC 8q24 translocation - how to treat?
    Leuk Lymphoma. 2017 Oct 12:1-7. doi: 10.1080/10428194.2017.1387914.
    PubMed     Text format     Abstract available


  234. QUNAJ L, Castillo JJ, Olszewski AJ
    Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.
    Leuk Lymphoma. 2017 Oct 11:1-9. doi: 10.1080/10428194.2017.1387912.
    PubMed     Text format     Abstract available


  235. VITAGLIANO O, Trastulli F, Cacace F, Leone S, et al
    Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
    Leuk Lymphoma. 2017 Oct 11:1-4. doi: 10.1080/10428194.2017.1387910.
    PubMed     Text format    


  236. CENCINI E, Puccini B, Rigacci L, Fabbri A, et al
    Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.
    Leuk Lymphoma. 2017 Oct 10:1-7. doi: 10.1080/10428194.2017.1387909.
    PubMed     Text format     Abstract available


  237. SU C, Nguyen KA, Bai HX, Balaji D, et al
    Comparison of chemoradiotherapy with radiotherapy alone for early-stage extranodal natural killer/T-cell lymphoma, nasal type in elderly patients.
    Leuk Lymphoma. 2017 Oct 5:1-7. doi: 10.1080/10428194.2017.1379078.
    PubMed     Text format     Abstract available


  238. JACHIET V, Mekinian A, Carrat F, Grignano E, et al
    Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study.
    Leuk Lymphoma. 2017 Oct 3:1-7. doi: 10.1080/10428194.2017.1379075.
    PubMed     Text format     Abstract available


    September 2017
  239. ZINTER MS, Melton A, Sabnis AJ, Dvorak CC, et al
    Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale.
    Leuk Lymphoma. 2017 Sep 28:1-4. doi: 10.1080/10428194.2017.1382697.
    PubMed     Text format    


  240. XU ZZ, Shen JK, Zhao SQ, Li JM, et al
    Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Sep 27:1-10. doi: 10.1080/10428194.2017.1379077.
    PubMed     Text format     Abstract available


  241. KAMRAN SC, Jacene HA, Chen YH, Mauch PM, et al
    Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD x two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.
    Leuk Lymphoma. 2017 Sep 22:1-7. doi: 10.1080/10428194.2017.1376745.
    PubMed     Text format     Abstract available


  242. MAZIARZ RT, Hao Y, Guerin A, Gauthier G, et al
    Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Sep 21:1-10. doi: 10.1080/10428194.2017.1375100.
    PubMed     Text format     Abstract available


  243. HERTING F, Friess T, Umana P, Middleton S, et al
    Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Sep 15:1-4. doi: 10.1080/10428194.2017.1376740.
    PubMed     Text format    


  244. BENTUR OS, Gurion R, Gafter-Gvili A, Gatt M, et al
    Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?
    Leuk Lymphoma. 2017 Sep 13:1-9. doi: 10.1080/10428194.2017.1375102.
    PubMed     Text format     Abstract available


  245. DIMOU M, Roumelioti M, Dimitrakopoulou A, Bitsani C, et al
    High-grade B-cell lymphoma of the peritoneum as a result of transformation of a CD5-negative monoclonal B lymphocytosis population in a patient with myelodysplastic syndrome treated with 5-azacytidine.
    Leuk Lymphoma. 2017 Sep 13:1-4. doi: 10.1080/10428194.2017.1375108.
    PubMed     Text format    


  246. L'ABBATE A, Iacobucci I, Lonoce A, Turchiano A, et al
    RALE051: a novel established cell line of sporadic Burkitt lymphoma.
    Leuk Lymphoma. 2017 Sep 11:1-4. doi: 10.1080/10428194.2017.1372580.
    PubMed     Text format     Abstract available


  247. JIANG L, Si T, Yu M, Zeng X, et al
    The tumor suppressive role of inhibin betaA in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Sep 7:1-11. doi: 10.1080/10428194.2017.1372574.
    PubMed     Text format     Abstract available


  248. ARBOE B, Halgren Olsen M, Duun-Henriksen AK, Gorlov JS, et al
    Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2017 Sep 4:1-10. doi: 10.1080/10428194.2017.1369061.
    PubMed     Text format     Abstract available


  249. RAESS PW, Moore SR, Cascio MJ, Dunlap J, et al
    MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes.
    Leuk Lymphoma. 2017 Sep 3:1-8. doi: 10.1080/10428194.2017.1370547.
    PubMed     Text format     Abstract available


  250. CHOWDHRY AK, Fung C, Chowdhry VK, Bergsma D, et al
    A population-based study of prognosis and survival in patients with second primary thyroid cancer after Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Sep 1:1-8. doi: 10.1080/10428194.2017.1369063.
    PubMed     Text format     Abstract available


    August 2017
  251. WINTER A, Rybicki L, Shah SN, Jagadeesh D, et al
    Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2017 Aug 30:1-7. doi: 10.1080/10428194.2017.1369065.
    PubMed     Text format     Abstract available


  252. DUVIC M, Bates SE, Piekarz R, Eisch R, et al
    Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.
    Leuk Lymphoma. 2017 Aug 30:1-8. doi: 10.1080/10428194.2017.1361022.
    PubMed     Text format     Abstract available


  253. MEIGNAN M, Cottereau AS
    Interim PET in lymphoma: from Deauville to Peking criteria. On the road, again....
    Leuk Lymphoma. 2017 Aug 30:1-3. doi: 10.1080/10428194.2017.1368078.
    PubMed     Text format    


  254. HIEMCKE-JIWA LS, Leguit RJ, Radersma-van Loon JH, Westerweel PE, et al
    Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement.
    Leuk Lymphoma. 2017 Aug 29:1-4. doi: 10.1080/10428194.2017.1369074.
    PubMed     Text format    


  255. PAUL U, Richter J, Stuhlmann-Laiesz C, Kreuz M, et al
    Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC.
    Leuk Lymphoma. 2017 Aug 25:1-9. doi: 10.1080/10428194.2017.1365851.
    PubMed     Text format     Abstract available


  256. EL-GALALY TC, Cheah CY
    Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission.
    Leuk Lymphoma. 2017 Aug 22:1-3. doi: 10.1080/10428194.2017.1365863.
    PubMed     Text format    


  257. GUIDOT DM, Switchenko JM, Nastoupil LJ, Koff JL, et al
    Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.
    Leuk Lymphoma. 2017 Aug 10:1-8. doi: 10.1080/10428194.2017.1361032.
    PubMed     Text format     Abstract available


  258. PARIKH A, Gopalakrishnan S, Freise KJ, Verdugo ME, et al
    Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Aug 10:1-9. doi: 10.1080/10428194.2017.1361024.
    PubMed     Text format     Abstract available



  259. Wendtner C-M, and Gregor M. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2017. http://dx.doi.org/10.1080/10428194.2017.1330474.
    Leuk Lymphoma. 2017 Aug 10:1. doi: 10.1080/10428194.2017.1363546.
    PubMed     Text format    


  260. RYLAND GL, Jones K, McBean M, Khot A, et al
    Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry.
    Leuk Lymphoma. 2017 Aug 9:1-4. doi: 10.1080/10428194.2017.1361029.
    PubMed     Text format    


  261. HU B, Younes A, Westin JR, Turturro F, et al
    Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Aug 9:1-8. doi: 10.1080/10428194.2017.1359741.
    PubMed     Text format     Abstract available


  262. BUR H, Haapasaari KM, Turpeenniemi-Hujanen T, Kuittinen O, et al
    Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patients.
    Leuk Lymphoma. 2017 Aug 8:1-11. doi: 10.1080/10428194.2017.1344840.
    PubMed     Text format     Abstract available


  263. KATSUSHIMA H, Fukuhara N, Konosu-Fukaya S, Himuro M, et al
    Does double-hit follicular lymphoma with translocations of MYC and BCL2 change the definition of transformation?
    Leuk Lymphoma. 2017 Aug 3:1-5. doi: 10.1080/10428194.2017.1357172.
    PubMed     Text format    


  264. ZHANG Y, Fan Y, Ying Z, Song Y, et al
    Can the SUVmax-liver-based interpretation improve prognostic accuracy of interim and posttreatment 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma?
    Leuk Lymphoma. 2017 Aug 3:1-10. doi: 10.1080/10428194.2017.1357171.
    PubMed     Text format     Abstract available


  265. JURCZAK W, Ramanathan S, Giri P, Romano A, et al
    Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2017 Aug 3:1-9. doi: 10.1080/10428194.2017.1357175.
    PubMed     Text format     Abstract available


    July 2017
  266. PAPIN A, Le Gouill S, Chiron D
    Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
    Leuk Lymphoma. 2017 Jul 31:1-9. doi: 10.1080/10428194.2017.1357177.
    PubMed     Text format     Abstract available


  267. SANTIAGO V, Lazaryan A, McClune B, McKenna RW, et al
    Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome.
    Leuk Lymphoma. 2017 Jul 21:1-9. doi: 10.1080/10428194.2017.1352094.
    PubMed     Text format     Abstract available


  268. SHLIAKHTSITSAVA K, Romero SAD, Dewald SR, Su HI, et al
    Pregnancy and child health outcomes in pediatric and young adult leukemia and lymphoma survivors: a systematic review.
    Leuk Lymphoma. 2017 Jul 21:1-17. doi: 10.1080/10428194.2017.1352097.
    PubMed     Text format     Abstract available


  269. SANCHEZ-GONZALEZ B, Torres E, Ferraro Rosset MP, Calafell M, et al
    Rituximab subcutaneous in B-cell non-Hodgkin lymphoma: clinical experience in a single center.
    Leuk Lymphoma. 2017 Jul 21:1-3. doi: 10.1080/10428194.2017.1349906.
    PubMed     Text format    


  270. AMMANN EM, Shanafelt TD, Wright KB, McDowell BD, et al
    Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.
    Leuk Lymphoma. 2017 Jul 18:1-7. doi: 10.1080/10428194.2017.1349905.
    PubMed     Text format     Abstract available


  271. HILL BT, Smith MR, Shelley M, Jagadeesh D, et al
    A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Jul 11:1-5. doi: 10.1080/10428194.2017.1347932.
    PubMed     Text format     Abstract available


  272. SOUZA BMB, De Vito FB, Calado ML, Silva MV, et al
    Evaluation of the cytotoxic response mediated by perforin and granzyme B in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Jul 6:1-7. doi: 10.1080/10428194.2017.1341978.
    PubMed     Text format     Abstract available


    June 2017
  273. LAI C, Roschewski M, Melani C, Pittaluga S, et al
    MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
    Leuk Lymphoma. 2017 Jun 22:1-4. doi: 10.1080/10428194.2017.1339882.
    PubMed     Text format    


  274. KIM J, Song YS, Lee JS, Lee WW, et al
    Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores.
    Leuk Lymphoma. 2017 Jun 20:1-8. doi: 10.1080/10428194.2017.1339877.
    PubMed     Text format     Abstract available


  275. CHAO C, Silverberg MJ, Chen LH, Xu L, et al
    Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Jun 13:1-9. doi: 10.1080/10428194.2017.1334121.
    PubMed     Text format     Abstract available


  276. VONDERHEID EC, Hou JS
    CD4+CD26- lymphocytes are useful to assess blood involvement and define B ratings in cutaneous T cell lymphoma.
    Leuk Lymphoma. 2017 Jun 9:1-10. doi: 10.1080/10428194.2017.1334123.
    PubMed     Text format     Abstract available


  277. HORING E, Staiger AM, Lenze D, Horn H, et al
    Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin.
    Leuk Lymphoma. 2017 Jun 5:1-4. doi: 10.1080/10428194.2017.1330469.
    PubMed     Text format    


  278. ROBAK T, Huang H, Jin J, Zhu J, et al
    Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study.
    Leuk Lymphoma. 2017 Jun 5:1-8. doi: 10.1080/10428194.2017.1321750.
    PubMed     Text format     Abstract available


  279. GAUTAM A, Zhu Y, Ma E, Lee SY, et al
    Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
    Leuk Lymphoma. 2017 Jun 5:1-8. doi: 10.1080/10428194.2017.1324160.
    PubMed     Text format     Abstract available


  280. HODKOFF A, Bentley P, Xu X
    Loss of CD3 and TCRgammadelta expression in a relapsed hepatosplenic T-cell lymphoma.
    Leuk Lymphoma. 2017 Jun 2:1-3. doi: 10.1080/10428194.2017.1326033.
    PubMed     Text format    


  281. HAZAR V, Kesik V, Karasu GT, Ozturk G, et al
    Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry.
    Leuk Lymphoma. 2017 Jun 2:1-12. doi: 10.1080/10428194.2017.1330472.
    PubMed     Text format     Abstract available


  282. P VASSILAKOPOULOS T, Levidou G, Milionis V, Hartmann S, et al
    Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon-gamma expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications.
    Leuk Lymphoma. 2017 Jun 2:1-13. doi: 10.1080/10428194.2017.1289520.
    PubMed     Text format     Abstract available


    May 2017
  283. REBOURSIERE E, Gac AC, Garnier A, Salaun V, et al
    Increased frequencies of circulating and tumor-resident Vdelta1+ T cells in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 May 31:1-9. doi: 10.1080/10428194.2017.1321751.
    PubMed     Text format     Abstract available


  284. HESS G, Rule S, Jurczak W, Jerkeman M, et al
    Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
    Leuk Lymphoma. 2017 May 30:1-9. doi: 10.1080/10428194.2017.1326034.
    PubMed     Text format     Abstract available


  285. FAN Y, Zhang Y, Yang Z, Ying Z, et al
    Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUVmax-liver-based interpretation for predicting the outcome in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 May 23:1-9. doi: 10.1080/10428194.2016.1277384.
    PubMed     Text format     Abstract available


  286. NAGAI H, Shimomura T, Takeuchi M, Hanada S, et al
    Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma.
    Leuk Lymphoma. 2017 May 16:1-7. doi: 10.1080/10428194.2017.1319054.
    PubMed     Text format     Abstract available


  287. XIAO X, Huang H, Chen J, Jiang Y, et al
    Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 May 16:1-5. doi: 10.1080/10428194.2017.1317096.
    PubMed     Text format    


  288. WAGNER-JOHNSTON ND, Lensing S, Noy A, Ratner L, et al
    High frequency of identical clonal immunoglobulin DNA in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphoma: prospective multicenter trial of the AIDS malignancies consortium (AMC 064).
    Leuk Lymphoma. 2017 May 16:1-4. doi: 10.1080/10428194.2017.1317095.
    PubMed     Text format     Abstract available


  289. DYSHLOVOY SA, Rast S, Hauschild J, Otte K, et al
    Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells.
    Leuk Lymphoma. 2017 May 16:1-11. doi: 10.1080/10428194.2017.1317091.
    PubMed     Text format     Abstract available


  290. SUN HL, Atenafu EG, Tsang R, Kukreti V, et al
    Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.
    Leuk Lymphoma. 2017 May 15:1-8. doi: 10.1080/10428194.2017.1307980.
    PubMed     Text format     Abstract available


  291. SKAMENE T, Crump M, Savage KJ, Reiman T, et al
    Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.
    Leuk Lymphoma. 2017 May 15:1-9. doi: 10.1080/10428194.2017.1312379.
    PubMed     Text format     Abstract available


  292. GUSS ZD, Madkhali A, Chen Q, Zhang Y, et al
    Intensity-modulated involved-site radiation therapy for non-Hodgkin lymphoma of the head and neck.
    Leuk Lymphoma. 2017 May 9:1-3. doi: 10.1080/10428194.2017.1312388.
    PubMed     Text format    


  293. HO JC, Dabaja BS, Milgrom SA, Smith GL, et al
    Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 May 9:1-12. doi: 10.1080/10428194.2017.1312381.
    PubMed     Text format     Abstract available


    April 2017
  294. DRENNAN AC, Rui L
    HiJAKing the epigenome in leukemia and lymphoma.
    Leuk Lymphoma. 2017 Apr 12:1-8. doi: 10.1080/10428194.2017.1312370.
    PubMed     Text format     Abstract available


  295. GUPTA NK, Wang CC, Mannis GN, Yu JJ, et al
    Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.
    Leuk Lymphoma. 2017 Apr 10:1-4. doi: 10.1080/10428194.2017.1312374.
    PubMed     Text format    


  296. VALDEZ BC, Li Y, Murray D, Liu Y, et al
    The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
    Leuk Lymphoma. 2017 Apr 10:1-12. doi: 10.1080/10428194.2017.1306647.
    PubMed     Text format     Abstract available


  297. WASHIO K, Oka T, Abdalkader L, Muraoka M, et al
    Gene expression analysis of hypersensitivity to mosquito bite, chronic active EBV infection and NK/T-lymphoma/leukemia.
    Leuk Lymphoma. 2017 Apr 3:1-12. doi: 10.1080/10428194.2017.1304762.
    PubMed     Text format     Abstract available


  298. BARRACLOUGH AA, Cheah CY
    Three different hematologists, three different answers: how should we treat concurrent systemic and central nervous system lymphoma?
    Leuk Lymphoma. 2017 Apr 3:1-3. doi: 10.1080/10428194.2017.1307364.
    PubMed     Text format    


  299. HERLING M, Rengstl B, Scholtysik R, Hartmann S, et al
    Concepts in mature T-cell lymphomas - highlights from an international joint symposium on T-cell immunology and oncology().
    Leuk Lymphoma. 2017;58:788-796.
    PubMed     Text format     Abstract available


    March 2017
  300. WU SC, Chapman JR, Vega F, Abrahams N, et al
    Hepatosplenic T-cell lymphoma associated with membranoproliferative glomerulonephritis.
    Leuk Lymphoma. 2017 Mar 28:1-4. doi: 10.1080/10428194.2017.1307358.
    PubMed     Text format    


  301. EL CHEIKH J, Massoud R, Haffar B, Fares E, et al
    Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.
    Leuk Lymphoma. 2017 Mar 28:1-3. doi: 10.1080/10428194.2017.1307362.
    PubMed     Text format    


  302. KOSTOS L, Chai KL, Tam CS, Bazargan A, et al
    The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Mar 23:1-4. doi: 10.1080/10428194.2017.1281414.
    PubMed     Text format    


  303. YOON KA, Kim MK, Eom HS, Lee H, et al
    Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Mar 22:1-6. doi: 10.1080/10428194.2017.1300893.
    PubMed     Text format     Abstract available


  304. BORCHMANN S, von Tresckow B
    Novel agents in classical Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Mar 20:1-12. doi: 10.1080/10428194.2017.1300898.
    PubMed     Text format     Abstract available


  305. CEDERLEUF H, Hjort Jakobsen L, Ellin F, de Nully Brown P, et al
    Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study.
    Leuk Lymphoma. 2017 Mar 20:1-9. doi: 10.1080/10428194.2017.1300888.
    PubMed     Text format     Abstract available


  306. YASUHIRO T, Sawada W, Klein C, Kozaki R, et al
    Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 i
    Leuk Lymphoma. 2017;58:699-707.
    PubMed     Text format     Abstract available


  307. LADIKOU EE, Kassi E
    The emerging role of estrogen in B cell malignancies.
    Leuk Lymphoma. 2017;58:528-539.
    PubMed     Text format     Abstract available


    January 2017
  308. BHATT S, Sarosiek KA, Lossos IS
    Interleukin 21 - its potential role in the therapy of B-cell lymphomas.
    Leuk Lymphoma. 2017;58:17-29.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: